What is new for resveratrol? Is a new set of recommendations necessary?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    Resumé

    Numerous scientific papers have suggested health-promoting effects of resveratrol, including claims in the prevention of diseases such as coronary heart disease, diabetes, and cancer. Therefore, it was proposed that the scientific community needed to express recommendations on the human use of resveratrol. Such recommendations were formulated after the first international resveratrol conference in Denmark, Resveratrol2010. The working group stated that the evidence was "not sufficiently strong to justify recommendation for the chronic administration of resveratrol to human beings, beyond the dose which can be obtained from dietary sources." It was a disappointing conclusion relative to the positive claims about the therapeutic potential of resveratrol made by the media. However, since 2010, results from the first clinical trials on resveratrol have been made available. Because of these emerging results, it is necessary to formulate updated versions of the recommendations.
    OriginalsprogEngelsk
    TidsskriftNew York Academy of Sciences. Annals
    Vol/bind1290
    Sider (fra-til)1-11
    Antal sider11
    ISSN0077-8923
    DOI
    StatusUdgivet - 2013
    Begivenhed2nd international conferene of resveratrol and health - Leicester University, Leicester, Storbritannien
    Varighed: 5 dec. 20127 dec. 2012

    Konference

    Konference2nd international conferene of resveratrol and health
    LokationLeicester University
    LandStorbritannien
    ByLeicester
    Periode05/12/201207/12/2012

    Emneord

    • resveratrol

    Citer dette

    @article{739dddafb8e747049c12672b666ef3fa,
    title = "What is new for resveratrol?: Is a new set of recommendations necessary?",
    abstract = "Numerous scientific papers have suggested health-promoting effects of resveratrol, including claims in the prevention of diseases such as coronary heart disease, diabetes, and cancer. Therefore, it was proposed that the scientific community needed to express recommendations on the human use of resveratrol. Such recommendations were formulated after the first international resveratrol conference in Denmark, Resveratrol2010. The working group stated that the evidence was {"}not sufficiently strong to justify recommendation for the chronic administration of resveratrol to human beings, beyond the dose which can be obtained from dietary sources.{"} It was a disappointing conclusion relative to the positive claims about the therapeutic potential of resveratrol made by the media. However, since 2010, results from the first clinical trials on resveratrol have been made available. Because of these emerging results, it is necessary to formulate updated versions of the recommendations.",
    keywords = "resveratrol",
    author = "Ole Vang",
    year = "2013",
    doi = "10.1111/nyas.12173",
    language = "English",
    volume = "1290",
    pages = "1--11",
    journal = "New York Academy of Sciences. Annals",
    issn = "0077-8923",
    publisher = "Wiley-Blackwell Publishing, Inc",

    }

    What is new for resveratrol? Is a new set of recommendations necessary? / Vang, Ole.

    I: New York Academy of Sciences. Annals, Bind 1290, 2013, s. 1-11.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    TY - JOUR

    T1 - What is new for resveratrol?

    T2 - Is a new set of recommendations necessary?

    AU - Vang, Ole

    PY - 2013

    Y1 - 2013

    N2 - Numerous scientific papers have suggested health-promoting effects of resveratrol, including claims in the prevention of diseases such as coronary heart disease, diabetes, and cancer. Therefore, it was proposed that the scientific community needed to express recommendations on the human use of resveratrol. Such recommendations were formulated after the first international resveratrol conference in Denmark, Resveratrol2010. The working group stated that the evidence was "not sufficiently strong to justify recommendation for the chronic administration of resveratrol to human beings, beyond the dose which can be obtained from dietary sources." It was a disappointing conclusion relative to the positive claims about the therapeutic potential of resveratrol made by the media. However, since 2010, results from the first clinical trials on resveratrol have been made available. Because of these emerging results, it is necessary to formulate updated versions of the recommendations.

    AB - Numerous scientific papers have suggested health-promoting effects of resveratrol, including claims in the prevention of diseases such as coronary heart disease, diabetes, and cancer. Therefore, it was proposed that the scientific community needed to express recommendations on the human use of resveratrol. Such recommendations were formulated after the first international resveratrol conference in Denmark, Resveratrol2010. The working group stated that the evidence was "not sufficiently strong to justify recommendation for the chronic administration of resveratrol to human beings, beyond the dose which can be obtained from dietary sources." It was a disappointing conclusion relative to the positive claims about the therapeutic potential of resveratrol made by the media. However, since 2010, results from the first clinical trials on resveratrol have been made available. Because of these emerging results, it is necessary to formulate updated versions of the recommendations.

    KW - resveratrol

    U2 - 10.1111/nyas.12173

    DO - 10.1111/nyas.12173

    M3 - Journal article

    VL - 1290

    SP - 1

    EP - 11

    JO - New York Academy of Sciences. Annals

    JF - New York Academy of Sciences. Annals

    SN - 0077-8923

    ER -